Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead And Novartis Unveil EU Marketing Plans For CAR-T Therapies, But Hurdles Remain

Aug 28 2018

• By John Davis

Hurdles — Pricing and reimbursement has to be agreed country-by-country in Europe • Source: Shutterstock

Related Content

EU CAR-T Race Tightens After Yescarta Reverts To Standard Review

Apr 23 2018

France To Speed Up Patient Access To Unapproved Drugs

Aug 22 2018

First CAR T-Cell Therapies OK'd In EU: Novartis's Kymriah And Kite's Yescarta

Jun 29 2018

Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern

Jul 18 2018

As Gilead Seeks New CEO, Second Quarter Shows Stability

Jul 26 2018

Related Companies

Novartis AG

Gilead Sciences, Inc.

Additional Topics

Europe Approvals Commercial Cost Effectiveness Manufacturing BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.